Fertility warning
This medicine may affect fertility.
Leaflet MEKINIST 1mg film-coated tablets
- Product code:
- W62209001
- Quantity:
- 7
- Indicated for:
- melanoma
- Route of administration:
- oral
- Substance:
- trametinib (tyrosine kinase inhibitor)
- ATC
- L01EE01 — Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mitogen-activated protein kinase (MEK) inhibitors
Precautions:
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Avoid grapefruit
Avoid grapefruit and grapefruit juice.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Cardiac risk / QT prolongation / arrhythmias
This medicine may increase the risk of heart rhythm disturbances.
Trametinib is a MEK kinase inhibitor used in the treatment of advanced or metastatic melanoma with BRAF V600 mutations. It works by blocking the MAPK/ERK signaling pathway, which is hyperactivated in tumor cells with BRAF mutations, thereby inhibiting their growth and proliferation.
Trametinib is administered orally, usually once daily, with the dose adjusted based on patient response and tolerability. It is often used in combination with dabrafenib, a BRAF inhibitor, to enhance treatment efficacy.
Common side effects include skin rashes, diarrhea, fatigue, nausea, and peripheral edema. In rare cases, severe adverse reactions such as cardiomyopathy, pulmonary function impairment, or ocular toxicity may occur. Regular monitoring of cardiac function and other clinical parameters is essential during treatment.
Trametinib is an innovative therapeutic option for patients with advanced melanoma, contributing to prolonged survival and improved quality of life.
Trametinib is administered orally, usually once daily, with the dose adjusted based on patient response and tolerability. It is often used in combination with dabrafenib, a BRAF inhibitor, to enhance treatment efficacy.
Common side effects include skin rashes, diarrhea, fatigue, nausea, and peripheral edema. In rare cases, severe adverse reactions such as cardiomyopathy, pulmonary function impairment, or ocular toxicity may occur. Regular monitoring of cardiac function and other clinical parameters is essential during treatment.
Trametinib is an innovative therapeutic option for patients with advanced melanoma, contributing to prolonged survival and improved quality of life.
General data about MEKINIST 1mg
- Substance:
- trametinib
- Date of latest medicines list:
- 01-12-2022
- Product code:
- W62209001
- Concentration:
- 1mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 7
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for trametinib
Concentrations available for trametinib
- 0.05mg/ml
- 0.5mg
- 1mg
- 2mg